ClinicalTrials.gg
RecruitingNCT07213492BTBDUpdated Oct 6, 2026

Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder

An interventional study of Group-Based Psychoeducation and Peer Support in Bipolar Disorder (BD) and Psychosis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by McMaster University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Bipolar Disorder with a site in Canada — 24 open to participants now, 28 under way, 4 of them phase 3. Bipolar Disorder · Canada.

Planned enrollment
99th of 118
10 · median 42
Started
2026
with 5 others
No phase
57 of 134
16 open now
Primary completion
2027-05
later than 10 of 27 live
Registered
131st of 134
by date

Among the 134 studies in Bipolar Disorder with a site in Canada, this one is the 99th largest by planned enrollment of the 118 interventional ones that give a count, is one of 6 that started in 2026, is one of 57 with no phase, reaches primary completion later than 10 of the 27 other live ones, and was the 131st registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

24 of the 134 studies in Bipolar Disorder with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Bipolar Disorder with a site in Canada, or all of them as a file.
02

Study summary

People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.

Read the detailed description

This is a 6-month, open-label pilot study of the feasibility, acceptability, and preliminary effectiveness of a multimodal transitional-care intervention for individuals with BD who have recently been discharged from the hospital. The intervention comprises a brief group psychoeducation program (6 clinician-facilitated sessions delivered over up to 8 weeks), individualized peer support (biweekly one-on-one sessions for \~12 total across 6 months), and optional personalized support for participants' primary healthcare providers (two collaborative sessions over 6 months offering guideline-based recommendations and access/training to a clinical decision-support app). Ten patient-participants who meet the inclusion criteria will be enrolled over 6 months; this sample will be used to estimate recruitment, retention, adherence, satisfaction, and safety parameters, and to inform power and procedures for a subsequent randomized controlled trial. Participants will be recruited from St. Joseph's Healthcare Hamilton (SJHH) outpatient clinics, the community and the ENABLE research registry at SJHH (Hamilton, ON, Canada). Eligible adults are 18-35 years old with a BD diagnosis within the past 24 months and a history of psychosis and/or limited illness insight; all must meet inclusion/exclusion criteria and provide written informed consent. After obtaining consent, eligibility will be confirmed with the Mini-International Neuropsychiatric Interview (MINI) and the Mood Disorders Insight Scale (MDIS). Study visits occur at three timepoints: baseline, post-psychoeducation, and post-multimodal intervention (6 months). At each assessment time point, clinicians and/or patient-participants will complete validated measures; socio-demographic and clinical history will be collected at baseline. Feasibility will be assessed through recruitment, enrollment, adherence (session attendance/completion), and retention metrics; acceptability through patient-participant and healthcare-provider satisfaction questionnaires; and safety through prospective monitoring of emergent symptoms, acute relapse, emergency visits, hospitalizations, and suicide-related events. Data will be summarized primarily with descriptive statistics (means, standard deviations, frequencies); exploratory pre-post comparisons (e.g., t-tests or chi-square) will evaluate the signal of change in symptoms, insight, functioning, lifestyle, and quality of life. The results of this study will determine whether delivering a structured psychoeducation + peer-support + provider-support care pathway during the transition from hospital to community is feasible and acceptable for early-stage BD, and will guide sample-size calculations, procedures, and implementation strategies for a subsequent randomized controlled trial.

03

Conditions studied

  • Bipolar Disorder (BD)
  • Psychosis

Keywords

  • Bipolar Disorder
  • Psychoeducation
  • Insight
  • Psychosis
  • Multimodal Intervention
  • Early-Stage Bipolar Disorder
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Patient-participants must be between 18 and 35 years old.
  • Diagnosis: Must have been diagnosed with bipolar disorder within the past 24 months.
  • Clinical Features: Must have experienced psychosis and/or a lack of insight into their illness at the time of enrollment.
  • Language Proficiency: Must be able to understand and speak English.

Exclusion criteria

Exclusion Criteria:

  • Severe Psychiatric Conditions: Individuals with a severe psychiatric condition that would prevent them from safely engaging in the intervention.
  • Cognitive or Medical Impairment: Those with significant cognitive impairment or a medical condition that interferes with their ability to participate in psychoeducation or peer-support sessions.
  • Substance Use Disorder: Individuals with an active substance use disorder that may impact adherence to the intervention.
  • Language Barriers: Participants who do not speak English and are unable to engage in study sessions without language support.
  • Concurrent Participation in Similar Programs: Individuals who are already enrolled in another structured psychoeducational or peer-support program that could interfere with study outcomes.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Multi-Modal Transitional Care Intervention

    Participants receive a 6-month structured intervention including: (1) 6 sessions of group-based psychoeducation, (2) biweekly peer support for individuals and families, and (3) two sessions of personalized clinical guidance for community healthcare providers.

    Behavioral: Group-Based Psychoeducation · Behavioral: Peer Support · Behavioral: Personalized Support for Community Healthcare Provider

Interventions

  • BehavioralGroup-Based Psychoeducation

    Participants attend a six-session, group-based psychoeducation program delivered over 8 weeks. Sessions focus on improving insight into bipolar disorder, relapse prevention, lifestyle strategies (e.g., sleep, nutrition, substance use), and digital literacy. The aim is to enhance understanding of illness and support long-term functioning.

  • BehavioralPeer Support

    Trained peer support workers provide biweekly sessions over 6 months to participants. The sessions are based on the CANMAT/ISBD Patient and Family Guide and include emotional support, psychoeducation, and shared experience. Each participant receives up to 12 sessions aimed at improving engagement and understanding of illness.

  • BehavioralPersonalized Support for Community Healthcare Provider

    The research team provides two personalized support sessions over 6 months to each participant's healthcare provider (e.g., family doctor or psychiatrist). Support includes treatment recommendations based on the CANMAT/ISBD 2018 Guidelines and training on the C-IMPACT BD web-based clinical decision support tool.

06

What researchers measure

Primary outcomes

  1. Feasibility of the Multi-Modal Transitional Care Intervention

    Feasibility will be assessed using three descriptive indicators: 1) Recruitment rate: the proportion of eligible patient-participants and community healthcare providers who consent to participate. 2) Retention rate: the proportion of enrolled participants who remain in the study until the final follow-up. 3) Intervention adherence: participant adherence to each intervention component, including the number of sessions attended and number of dropouts. Each indicator will be analyzed separately to determine the feasibility of implementing the multi-modal transitional care intervention.

    Time frame: From enrollment to the end of intervention at 6 months.

  2. Acceptability of the Multi-Modal Transitional Care Intervention

    Acceptability will be measured using post-intervention surveys completed by patient-participants and community healthcare providers. Surveys will assess satisfaction and perceived usefulness of the intervention using Likert-scale items, with the option to provide additional information via open-ended questions.

    Time frame: Administered at the end of the intervention (Month 6).

Secondary outcomes

  1. Change in Depression Symptoms (MADRS)

    Clinician-rated 10-item scale assessing depressive symptoms over the past 7 days. Items are rated on a 7-point Likert scale, with higher scores indicating more severe symptoms.

    Time frame: Baseline and Month 6 (end of intervention).

  2. Change in Mania Symptoms (YMRS)

    Clinician-rated 11-item scale assessing manic symptoms using clinical interview and observation. Items scored 0-4 or 0-8, with higher scores indicating more severe mania.

    Time frame: Baseline and Month 6 (end of intervention).

  3. Change in Anxiety Symptoms (GAD-7)

    7-item self-report scale assessing anxiety over the past 2 weeks. Items scored 0-3; higher scores reflect greater anxiety.

    Time frame: Baseline, Mid-intervention (Month 3), and Month 6 (end of intervention).

  4. Change in Depression Severity (Patient Health Questionnaire) (PHQ-9)

    9-item self-report scale evaluating the presence and severity of depression symptoms over the past 2 weeks. Each item scored 0-3; higher scores indicate greater severity.

    Time frame: Baseline, Mid-intervention (Month 3), and Month 6 (end of intervention).

  5. Change in Insight (MDIS)

    Self-report scale assessing insight in mood disorders. Participants respond "Agree," "Disagree," or "Unsure." Higher scores indicate better insight.

    Time frame: Baseline and Month 6 (end of intervention).

  6. Change in Psychosocial Functioning (FAST)

    Clinician-administered scale assessing functioning across six domains (autonomy, work, cognition, finances, relationships, leisure). Each item rated 0-3.

    Time frame: Baseline and Month 6 (end of intervention).

  7. Change in Cognitive Complaints (COBRA)

    16-item self-report questionnaire measuring cognitive dysfunction in bipolar disorder. Each item scored 0-3; higher scores indicate more impairment.

    Time frame: Baseline and Month 6 (end of intervention).

  8. Change in Quality of Life (Q-LES-Q-SF)

    16-item self-report scale assessing satisfaction and enjoyment in multiple life areas over the past week. Items rated on a 5-point scale.

    Time frame: Baseline, Mid-intervention (Month 3), and Month 6 (end of intervention).

  9. Change in Lifestyle Behaviours (SMILE)

    Self-report scale measuring behaviours across seven lifestyle domains (diet and nutrition, substance use, physical activity, stress management, restorative sleep, social support, and environmental exposures). Items scored on a 4-point scale; higher scores reflect healthier lifestyle.

    Time frame: Baseline and Month 6 (end of intervention).

Other outcomes

  1. Safety Monitoring: Relapse, Hospitalization, and Risk

    Monitoring and documentation of adverse events including psychiatric relapse, hospitalizations, and suicide attempts throughout the intervention period.

    Time frame: Throughout the 6-month intervention period.

  2. Sociodemographic Factors

    Demographic and clinical background data will be collected, including gender, age, ethnicity, marital status, education level, income, medical and psychiatric history, family history of psychiatric disorders, medication usage, and treatment history.

    Time frame: Baseline and Month 6 (end of intervention).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. PubMed 29536616 ↗
  • Gomes FA, Dumay H, Fagen J, Palma N, Milev R, Brietzke E. Does the Ranking Matter? A Retrospective Cohort Study Investigating the Impact of the 2018 CANMAT and ISBD Guidelines for the Management of Patients with Bipolar Disorder Treatment Recommendations for Acute Mania on Rehospitalization Rates. Can J Psychiatry. 2023 Aug;68(8):605-612. doi: 10.1177/07067437231156235. Epub 2023 Feb 21. PubMed 37551100 ↗
  • Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig TJ, Nordentoft M, Srihari VH, Guloksuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Severe JB, Kane JM. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-565. doi: 10.1001/jamapsychiatry.2018.0623. PubMed 29800949 ↗
  • Simjanoski M, de Azevedo Cardoso T, Frey BN, Minuzzi L, De Boni RB, Balanza-Martinez V, Kapczinski F. Lifestyle in bipolar disorder: A cross-sectional study. Span J Psychiatry Ment Health. 2023 Oct-Dec;16(4):244-250. doi: 10.1016/j.rpsm.2023.04.001. Epub 2023 May 26. PubMed 37839960 ↗
  • Ratheesh A, Hett D, Ramain J, Wong E, Berk L, Conus P, Fristad MA, Goldstein T, Hillegers M, Jauhar S, Kessing LV, Miklowitz DJ, Murray G, Scott J, Tohen M, Yatham LN, Young AH, Berk M, Marwaha S. A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early intervention. Int J Bipolar Disord. 2023 Jan 3;11(1):1. doi: 10.1186/s40345-022-00275-3. PubMed 36595095 ↗

Individual participant data

Plan to share: No — Currently, we do not have the plan of individual participant data (IPD) sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 11 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 9, 2025
StartActual
Jun 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213492
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Jun 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Fabiano A. Gomes, MD, Ph.D.
Contact
gomesfs@mcmaster.ca
905-522-1155 ext. 39520
Daniela Giansante, MSc
Contact
giansand@mcmaster.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion